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ABSTRACT 
Schizophrenia is a severe mental disorder affecting 0.4-1% of the population 
worldwide. It is characterized by impairments in the perception of reality and by 
significant social or occupational dysfunction. The disorder is one of the major 
contributors to the global burden of diseases. Studies of twins, families, and adopted 
children point to strong genetic components for schizophrenia, but environmental 
factors also play a role in the pathogenesis of disease. 
Molecular genetic studies have identified several potential positional candidate 
genes. The strongest evidence for putative schizophrenia susceptibility loci relates to 
the genes encoding dysbindin (DTNBP1) and neuregulin (NRG1), but studies lack 
impressive consistency in the precise genetic regions and alleles implicated. We 
have studied the role of three potential candidate genes by genotyping 28 single 
nucleotide polymorphisms in the DNTBP1, NRG1, and AKT1 genes in a large 
schizophrenia family sample consisting of 441 families with 865 affected 
individuals from Finland. Our results do not support a major role for these genes in 
the pathogenesis of schizophrenia in Finland. 
We have previously identified a region on chromosome 5q21-34 as a susceptibility 
locus for schizophrenia in a Finnish family sample. Recently, two studies reported 
association between the -aminobutyric acid type A receptor cluster of genes in this 
region and one study showed suggestive evidence for association with another 
regional gene encoding clathrin interactor 1 (CLINT1, also called Epsin 4 and 
ENTH). To further address the significance of these genes under the linkage peak in 
the Finnish families, we genotyped SNPs of these genes, and observed statistically 
significant association of variants between GABRG2 and schizophrenia. 
Furthermore, these variants also seem to affect the functioning of the working 
memory. 
Fetal events and obstetric complications are associated with schizophrenia. Rh 
incompatibility has been implicated as a risk factor for schizophrenia in several 
epidemiological studies. We conducted a family-based candidate-gene study that 
assessed the role of maternal-fetal genotype incompatibility at the RhD locus in 
schizophrenia. There was significant evidence for an RhD maternal-fetal genotype 
incompatibility, and the risk ratio was estimated at 2.3. This is the first candidate-
  
gene study to explicitly test for and provide evidence of a maternal-fetal genotype 
incompatibility mechanism in schizophrenia. 
In conclusion, in this thesis we found evidence that one GABA receptor subunit, 
GABRG2, is significantly associated with schizophrenia. Furthermore, it also seems 
to affect to the functioning of the working memory. In addition, an RhD maternal-
fetal genotype incompatibility increases the risk of schizophrenia by two-fold. 
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TIIVISTELMÄ 
Skitsofrenia on vakava mielenterveyden häiriö ja sitä esiintyy noin 0,4-1 % 
maailman väestöstä. Skitsofreniaa sairastavilla on ongelmia todellisuuden 
havainnoinnissa ja heidän sosiaalinen toimintansa on yleensä häiriintynyt. Perhe-, 
kaksois- ja adoptiotutkimusten perusteella skitsofrenialla on merkittävä 
perinnöllinen tausta, mutta ympäristötekijätkin vaikuttavat taudin syntyyn. 
Olemme aikaisemmissa tutkimuksissa löytäneet kromosomista 5 alueen, joka 
kytkeytyi skitsofreniaan perhemateriaalissamme. Aineistomme koostui  441 
perheestä käsittäen 865 skitsofreniaa sairastavaa ihmistä. Viime aikoina on tältä 
samalta alueelta löydetty useita geenejä, joiden variaatiot näyttäisivät altistavan 
skitsofrenialle. -aminovoihappo A-tyypin reseptoreiden alayksiköistä muodostuva 
geenirykelmä näyttäisi liittyvän suurentuneeseen riskiin sairastua tautiin. Halusimme 
tutkia näiden geenien roolia skitsofreniassa myös suomalaisessa väestössä 
analysoimalla niissä sijaisevia variaatioita. Havaitsimme, että GABRG2 geenin 
variaatiot näyttäisivät liittyvän skitsofrenian sairastumisriskiin. Lisäksi nämä 
variaatiot näyttivät liittyvän myös työmuistin toimintaan. Skitsofreniaa sairastavilla 
on keskimäärin huonontuneet kongnitiiviset toiminnot, joten löydös voi 
tulevaisuudessa avata uusia mahdollisuuksia työmuistin toiminnan tutkimuksessa.  
Viime aikaiset molkyyligeneettiset tutkimukset maailmalla ovat löytäneet useita 
lupaavia skitsofrenialle altistavia ehdokasgeenejä. Kaksi vahvinta ehdokasta ovat 
dysbindin (DTNBP1) ja neureguliini (NRG1), mutta tutkimukset eivät ole olleet 
aivan johdonmukaisia geenialueen ja alleelien suhteen. Tutkimme kolmen 
aikaisemmin skitsofreniaan yhdistetyn geenin (DNTBP1, NRG1, and AKT1) roolia 
suomalaisessa perhemateriaalissamme analysoimalla 28 yhden nukelotidin muutosta 
(SNP, single nucelotide polymorphism). Tulostemme valossa näiden kolmen geenin 
variaatiot eivät ole merkittäviä riskitekijöitä skitsofrenialle meidän väestössämme. 
Raskauden aikaiset komplikaatiot lisäävät sikiön riskiä sairastua skitsofreniaan noin 
kaksinkertaiseksi myöhemmin elämässä. Rhesus -veriryhmän yhteenopimattomuus 
on epidemiologisissa tutkimuksissa yhdistetty skitsofreniaan. Tämän veriryhmän 
yhteensopimattomuus voi vakavammillaan johtaa sikiön pahaan hemolyyttiseen 
tautiin. Tutkimme tätä äidin ja sikiön RhD geenin yhteensopimattomuutta 
skitsofrenia perheaineistossamme. RhD geenin yhteensopimattomuus äidin ja sikiön 
  
välillä nosti sikiön sairastumisriskiä 2,26-kertaiseksi meidän tutkimuksessamme. 
Tämä on maailmassa ensimmäin tutkimus, joka suoraan pystyi yhdistämään äidin ja 
sikiön yhteensopimattomuuden geenitasolla skitsofreniaan. On kuitenkin 
humioitava, että tutkimukseen osallistuneet henkilöt olivat syntyneet suurimmaksi 
osaksi ennen 70-lukua, joten anti-D-vasta-aineiden anto äidille ei ollut vakiintunut 
käytäntö Suomessa.  RhD geenin yhteensopimattomuuden roolia skitsofrenialle 
altistavana tekijänä myöhemmin syntyneiden joukossa ei tiedetä. 
Tässä väitöskirjassa löysimme viitteitä, että yhden GABA välittäjäainereseptorin 
(GABRG2) variaatiot perimässä altistavat skitsofrenialle. Osoitimme myös, että RhD 
veriryhmän yhteensopimattomuus äidin ja sikiön välillä näyttäisi lisäävän sikiön 
riskiä sairastua myöhemmin skitsofrenialle. 
 
 
Asiasanat: Skitsofrenia,  geneettinen assosiaatio analyysi, GABA reseptori, 
GABRG2, RhD, DNTBP1, NRG1, AKT1, CLINT1 
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ABBREVIATIONS 
3AF all Finland 
CNV copy-number variant 
DNA deoxyribonucleic acid 
DNTBP1 dystrobrevin-binding protein dysbindin 
DSM Diagnostic and Statistical Manual of Mental Disorders 
DZ dizygotic 
GABA gamma-aminobutyric acid 
HLA human leukocyte antigen 
HRR haplotype-relative risk 
ICD International Classification of Diseases 
IS internal isolate 
LC liability class 
LD linkage disequilibrium 
LOD logarithm of odds 
MFG maternal-fetal genotype 
MR morbid risk 
MZ monozygotic 
NA not applicable 
PCR polymerase chain reaction 
QTL quantitative trait locus 
Rh rhesus 
SNP single nucleotide polymorphism 
STR short tandem repeats 
TDT transmission disequilibrium test 
TRAX translin-associated factor X 
VCFS Velo-cardia-facial syndrome 
WAIS-R Weschsler Adult Intelligence Scale – revised 
WMS-R Wechsler Memory Scale – revised 
 10 
LIST OF ORIGINAL PUBLICATIONS 
This thesis is based on the following original articles referred to in the text by their 
Roman numerals: 
 
I Turunen JA*, Peltonen JO*, Pietilainen OP, Hennah W, Loukola A, 
Paunio T, Silander K, Ekelund J, Varilo T, Partonen T, Lönnqvist J, 
Peltonen L. The role of DTNBP1, NRG1, and AKT1 in the genetics of 
schizophrenia in Finland. Schizophr Res. 2007 Mar;91(1-3):27-36 
II Turunen JA, Paunio T, Tuulio-Henriksson AM, Hennah W, Ekelund J, 
Varilo T, Ylisaukko-oja T, Partonen T, Loukola A, Silander K, Lönnqvist 
J, Peltonen L. Variants in the GABRG2 gene are associated with 
schizophrenia. Submitted 
III  Palmer CG, Turunen JA, Sinsheimer JS, Minassian S, Paunio T, 
Lonnqvist J, Peltonen L, Woodward JA. RHD maternal-fetal genotype 
incompatibility increases schizophrenia susceptibility. Am J Hum Genet. 
2002 Dec;71(6):1312-9. 
IV  Minassian SL, Palmer CG, Turunen JA, Paunio T, Lönnqvist J, Peltonen 
L, Woodward JA, Sinsheimer JS. Incorporating serotypes into family 
based association studies using the MFG test. Ann Hum Genet. 2006 
Jul;70(Pt 4):541-53.  
 
 
 
*These authors contributed equally to this work 
These articles are reproduced with the kind permission of their copyright holders. 
 
 
 
 
 
 11 
 
 12 
1 INTRODUCTION 
Schizophrenia is a severe mental disorder characterized by impairments in the 
perception of reality and by significant social or occupational dysfunction. It is 
characterized by a constellation of features, including delusions, hallucinations, 
disorganized speech and behavior, flattened affect, and inability to initiate and 
persist in goal-directed activities. Schizophrenia has a lifetime prevalence of 0.4–1% 
worldwide (1-4). Studies of twins, families, and adopted children point to strong 
genetic components: for example, risk of the disease in a co-twin of an affected 
proband is 5-8 fold higher in monozygotic (46%) than in dizygotic (9%) twins (5-
10). Several environmental risk factors have also been suggested for schizophrenia, 
among them obstetric complications (11-13). 
The genetic mapping approach offers tools for identification of genetic components 
of diseases. Thus, it can eventually lead to better understanding of the biological 
basis of diseases, and ultimately to development of new treatments. The completion 
of the Human Genome Project and continuing cataloguing of variations within the 
human genome have offered effective tools for identification of the genetic risk 
factors for the disease. 
The following review will focus on the existing knowledge of the genetic 
background of schizophrenia. In the thesis work, current knowledge of the human 
genome variations, the efficient genotyping techniques, and novel statistical 
methods have been utilized to enlighten the genetic background of schizophrenia. 
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2 REVIEW OF THE LITERATURE 
2.1 Overview of schizophrenia 
2.1.1 Diagnosis 
 
Schizophrenia is a devastating psychiatric disorder affecting 0.4-1% of the 
population worldwide. The onset of the illness occurs typically in young adults, and 
leads to significant impairment in occupational and social functioning. The clinical 
picture of schizophrenia is heterogeneous, and no single symptom defines the 
disease. The disorder is equally prevalent in both sexes, but men tend to have 
slightly earlier onset, and a more severe course of the disorder. Even if the incidence 
of schizophrenia is relatively low, the disorder is one of the major contributors to the 
global burden of diseases (14). 
Currently, two parallel diagnosis methods for schizophrenia exist: the Diagnostic 
and Statistical Manual for Mental Disorders, fourth edition (DSM-IV) (table 1), and 
the International Classification of Diseases, tenth edition (ICD-10). The methods are 
essentially similar, and lead to the same kind of diagnostic definition of the disease. 
In the scientific literature, the DSM-IV is more widely used, and in the current thesis 
all diagnoses are based on the DSM-IV criteria. Diagnosis is based on the self-
reported experiences of the patient, in combination with secondary signs observed 
by psychiatrists, and documented information in patient records. No specific 
laboratory test for the disorder is available. 
By definition, schizophrenia is characterized by psychotic symptoms, which include 
delusions, hallucinations and disorganized thought and behaviour. These symptoms 
are historically called “positive” symptoms. “Negative” symptoms, on the other 
hand, involve the absence of normal behaviours, and include affective flattening, 
lack of pleasure in everyday life, diminished ability to initiate and sustain planned 
activities, and social withdrawal. Patients should have continuous signs of the 
disturbance for at least 6 months. Symptoms have to be so severe that normal 
functioning in work, interpersonal relations, or self-care is greatly disturbed. 
Although not directly included in the diagnostic criteria, schizophrenia is also 
characterized by cognitive deficits. Schizophrenia patients have severe problems 
with attention, memory, and executive functions. These deficits affect the functional 
capacity of the patients, and currently no treatment is available for definitely 
improving them. The studies have shown that the cognitive dysfunction observed in 
schizophrenia patients and their relatives is heritable. Thus, genetics can be used to 
study factors behind these traits. 
 14 
 
Table 1. Diagnostic criteria for schizophrenia according to the DSM-IV  (American 
Psychiatric Association 1994) 
      
   
A. Characteristic symptoms: Two or more of the following, each present for a significant 
portion of time during a 1-month period (or less if successfully treated): 
   
 1. Delusions 
 2. Hallucinations 
 3. Disorganized speech 
 4. Grossly disorganized or catatonic behaviour 
 5. Negative symptoms 
   
Only one Criterion A symptom is required if delusions are bizarre or hallucinations 
consist of a voice keeping up a running commentary on the person’s behaviour or 
thoughts, or two or more voices are conversing with each other. 
   
B. Social/occupational dysfunction: for a significant portion of the time since the onset 
of the disturbance, one or more major areas of functioning such as work, interpersonal 
relations, or self-care are markedly below the level achieved prior to the onset (or, when 
the onset is in childhood or adolescence, failure to achieve the expected level). 
   
C. Duration: Continuous signs of the disturbance persist for at least 6 months, of which 
at least one month should be of symptoms that meet Criterion A. The 6 months may 
include periods of prodromal and residual symptoms. 
   
D. Schizoaffective and mood disorder exclusion: Schizoaffective disorder and mood 
disorder with psychotic features have been ruled out because either no major depressive, 
manic, or mixed episodes have occurred concurrently with the active-phase symptoms, 
or if mood episodes have occurred during active-phase symptoms, their total duration 
has been brief relative to the active and residual periods. 
   
E. Substance/general medical condition exclusion: The disturbance is not due to the 
direct physiological effects of a substance or a general medical condition. 
   
F. Relationship to a pervasive developmental disorder: if there is a history of autistic 
disorder or another pervasive developmental disorder, the additional diagnosis of 
schizophrenia is made only if prominent delusions or hallucinations are also present for 
at least a month (or less if successfully treated). 
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2.1.2 Epidemiology 
 
Understanding the ‘‘epidemiological landscape’’ of schizophrenia requires many 
different types of descriptive studies in order to guide research to ultimately 
understand the etiology and pathology of the disease. 
In a recently published systematic review the incidence of schizophrenia was found 
to be 15.2 persons per 100,000 per year with variation between geographical 
locations. Males were slightly more likely to develop schizophrenia than females, as 
were migrants compared to native-born individuals. Individuals in urban sites are at 
higher risk for the disease than those with mixed urban/rural sites (15). Also, 
individuals born in the winter and spring have a slightly increased risk of developing 
schizophrenia (16).  
Prevalence measures the proportion of individuals who have a disorder at a specified 
time, or during a specified period. Lifetime prevalence is the proportion of 
individuals in the population who are alive on a given day and who have ever 
manifested a disorder, Saha and colleagues conducted a systematic review of the 
schizophrenia prevalence from 188 studies from 46 countries. They estimated that 
the median lifetime prevalence for schizophrenia is 4.0 per 1000 (3). The prevalence 
of schizophrenia did not vary between the sexes. The prevalence of the disease was 
higher in migrants than native-born individuals, and about 5% to 15% higher in 
people born during the winter than in those born at other times of the year (17).  
The age of onset vary between men and women. Men tend to show the first signs of 
disease during their early 20s, women during their mid and late 20s. In the vast 
majority of schizophrenic people, onset occurs between the ages of 15 and 45. 
 
2.1.3 Etiology and pathophysiology 
 
2 . 1 . 3 . 1  G e n e t i c s  o f  s c h i z o p h r e n i a  
 
Studies of twins, families, and adopted children point to strong genetic components 
for schizophrenia: for example, risk of the disease in a co-twin of an affected 
individual is higher in monozygotic (46%) than in dizygotic (9%) twins (5-10, 18, 
19). Several candidate genes have been proposed in the recent years, but conclusive 
 16 
evidence for any single gene is lacking. The genetics of schizophrenia is discussed 
in details in the section 2.3. 
 
2 . 1 . 3 . 2  E n v i r o n m e n t a l  f a c t o r s  
 
There is now growing evidence that adult chronic diseases can be programmed 
prenatally or in early infancy (20, 21). Stressful situations during pregnancy have 
been linked to increased risk for schizophrenia. Several maternal infections during 
pregnancy have been associated with increased later risk for schizophrenia: 
influenza (22), other respiratory tract infections (23), polio (24), rubella (25), and 
herpes simplex virus (26).  Furthermore, many other obstetric complications appear 
to increase the risk for schizophrenia. In a recent meta-analysis Cannon and 
colleagues (11) grouped the obstetric complications into three main categories: (1) 
complications of pregnancy (bleeding, diabetes, rhesus incompatibility, pre-
eclampsia); (2) abnormal fetal growth and development (low birth weight, high birth 
weight, congenital malformations, reduced head circumference), and (3) 
complications of delivery (uterine atony, asphyxia, emergency caesarean section). 
The overall odds ratio of the obstetric complications is estimated to be 2.0 (95% 
confidence interval 1.5 - 2.4) (11, 27, 28).  The individual risk factors for some of 
the most important obstetric risk factors are presented in table 2. It should be noted 
that obstetric complications are not specific, and these problems in the early life can 
also predispose to other chronic diseases. Nevertheless, the complications during 
pregnancy are a well-established risk factor for schizophrenia and should be taken 
into account in the future research. 
Rhesus (Rh) incompatibility can cause of hemolytic disease of the fetus and 
newborn. Hemolytic disease results from the transplacentally transmitted maternal 
antibodies against Rh factor D and can cause permanent neurological damage in the 
affected newborn. Epidemiological study found that the rate of schizophrenia was 
significantly higher in the Rh-incompatible group compared with the Rh-compatible 
group (29), which indicates that Rh imcombatibility may be risk factor for 
schizophrenia. 
People who later develop schizophrenia often appear to have more neuromotor, 
language and cognitive developmental deficits in the early childhood than control 
individuals. These individuals seem to have also social and emotional problems 
during childhood, but these may be a more general marker of risk for different kinds 
of psychiatric illnesses in adulthood (30). These developmental impairments have 
been thought to be genetically programmed, consistent with the hypothesis of 
schizophrenia as a neurodevelopmental disorder (31). 
 17 
Use of cannabis is associated with a two-fold risk for later schizophrenia (32, 33), 
and the use of cannabis in the early adulthood is linked with even higher risk for 
later development of the disease. The connection between schizophrenia and 
cannabis is not direct, and these findings need to be studied in more detailed. 
There have also been studies concerning the early rearing environment, which 
include whether or not the pregnancy was wanted (34), antenatal depression of the 
mother (35), atypical mother–infant interaction (11), poor mothering (35), and early 
parental loss (36), but evidence for these is rather weak and these results should be 
considered with caution. 
 18 
 
Table 2. Meta-Analysis of Eight Prospective Population-Based Studies of the 
Association Between Obstetric Complications and Schizophrenia. Adapted from 
Cannon and colleagues (11). 
        
    
Complicationa Odds ratio 95% CI p-value 
        
    
Diabetes in pregnancy 7.76 1.37-43.9 <0.03 
Placental abruption 4.02 0.89-18.12 0.07 
Birth weight <2000 g 3.89 1.40-10.84 0.009 
Emergency Cesarean section 3.24 1.40-7.50 0.006 
Congenital malformations 2.35 1.21-4.57 <0.02 
Uterine atony 2.29 1.51-3.50 <0.001 
Rhesus variablesb 2.00 1.01-3.96 <0.05 
Threatened premature delivery 1.98 0.79-4.90 0.14 
Asphyxia 1.74 1.15-2.62 0.008 
Bleeding in pregnancy 1.69 1.14-2.52 0.009 
Birth weight <2500 g 1.67 1.22-2.29 0.002 
Head circumference <32 cm 1.38 0.97-1.91 0.08 
Smoking in pregnancy 1.38 0.88-2.14 0.16 
Preeclampsia 1.36 0.99-1.85 0.05 
Anemia in pregnancy 1.26 0.69-2.28 0.45 
Gestational age <37 weeks 1.22 0.90-1.65 0.2 
Small for gestational age 1.21 0.91-1.61 0.19 
Induction of labor 1.18 0.89-1.56 0.25 
Apgar score <7 at 1 minute after birth 1.09 0.62-1.92 0.76 
Gestational age >42 weeks 1.08 0.69-1.68 0.72 
Child stayed in hospital after mother 
discharged 1.07 0.79-1.44 0.65 
Forceps delivery or vacuum extraction 1.07 0.85-1.35 0.48 
Birth length <49 cm 1.06 0.86-1.31 0.59 
Cephalopelvic disproportion 1.04 0.28-3.82 0.95 
Cord around neck 1.03 0.81-1.31 0.83 
        
    
aComplications presented in order of effect size.   
bIncludes rhesus incompatibility, rhesus-negative mother, and rhesus antibodies. 
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2 . 1 . 3 . 3  S t r u c t u r a l  a n d  f u n c t i o n a l  b r a i n  
a b n o r m a l i t i e s  
 
There are many kinds of macroscopic changes in the brains of schizophrenic 
individuals compared to the healthy individuals. The cerebral volume of the subjects 
with schizophrenia seems to be smaller, and the total ventricular volume of the 
subjects with schizophrenia is greater (37, 38). The following brain regions are most 
often implicated: the hippocampus (39, 40), the prefrontal and superior temporal 
neocortex (41, 42), and the thalamus (43). Several other brain abnormalities have 
been associated with schizophrenia; cortical thickness (44), cortical gyrification (45, 
46), hippocampal shape (47, 48), and cerebral asymmetry (49, 50). However, none 
of these changes are specific for schizophrnenia. 
The most repeated finding at the histological level is an abnormal distribution of 
neurons, especially interstitial white matter neurons, in the brains of the 
schizophrenics. Defects in the interstitial white matter neurons have been found in 
the dorsolateral prefrontal (51-53), middle and medial temporal (54) and inferior 
parietal (55) cortices. These kinds of abnormalities point to an early 
neurodevelopmental deficits in neuronal migration, survival, and connectivity (56). 
In the several studies, the cell bodies of pyramidal neurons in the hippocampus and 
neocortex were found to be smaller in brains of schizophrenic patients (57-61). 
Several other neuronal abnormalities have also been reported, but detailed 
description of them is beyond the scope of this review. An important finding is also 
that schizophrenia is not associated with an increased frequency of 
neurodegenerative disorders (62, 63). 
Most of these differences in brain structure and histology are only detected when 
comparing groups of people, and are not always observed in all individuals with 
schizophrenia. In conclusion, schizophrenia is beyond doubt a brain disorder, but the 
disease does not have a clear neuropathological signature in the macroscopical or 
histological level. 
 
 20 
2.2 Genetic mapping of complex diseases 
2.2.1 Human genome 
 
2 . 2 . 1 . 1  S t r u c t u r e  o f  t h e  h u m a n  g e n o m e  
 
The human genome, when referred to DNA content, consists of two genomes: a 
nuclear genome and a mitochondrial genome. The nuclear human genome contains a 
total of approximately 3 billion DNA base pairs in 24 distinct human chromosomes: 
22 autosomal chromosomes, and the sex-determining X and Y chromosomes. The 
“finished” human genome sequence was announced in 2004, and it covered 99% of 
the euchromatic genome (64). 
There are an estimated 20,000 protein-coding genes in the human genome. Genes 
make up of only about 2% of the human genome; the rest consists of noncoding 
regions, whose function is under an intense investigation. Comparative analyses of 
vertebrate sequences can identify coding and conserved non-coding regions, 
including regulatory elements (65, 66). Mammalian genomes contain highly 
conserved sequences that are not functionally transcribed, and these sequences 
comprise approximately 1–2% of the human genome (67). During evolution the 
human genome has accumulated a vast amount of repeated sequences that do not 
code for proteins (64, 68, 69). Repetitive sequences make up at least 50% of the 
human genome. Their role is not totally understood, but they are involved with 
chromosome structure and dynamics. 
 
 
2 . 2 . 1 . 2  V a r i a t i o n s  i n  t h e  h u m a n  g e n o m e  
 
Any two humans are approximately 99.9% identical in their DNA sequence (70, 71). 
Thus, the small fraction of DNA sequence that constitutes the genetic variation 
between individuals leads us to the roots of the disease susceptibility and the 
phenotypic variations. Historically, the first differences observed in the genome was 
aneuploidy, i.e. the presence of an abnormal number of chromosomes within a cell 
(72, 73). Later, larger rearrangements were observed using a microscope (74). These 
are usually larger than 3 Mb in size. 
The sequencing of the human genome has made it possible to better catalogue the 
variations among humans. The most abundant variation type in the human genome 
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is a single nucleotide polymorphism (SNP). It has been estimated that there are at 
least 10 million SNPs within the human populations (75). The human genome also 
has various repetitive elements that involve relatively short DNA sequences (for 
example, micro- and minisatellites), and small (usually <1 kb) insertions, deletions, 
inversions and duplications. During the last years it has become evident that larger 
structural variations in the human genome are also relatively common (76, 77). 
These are usually referred to as a copy-number variants (CNV), which are segments 
of DNA that is 1 kb or larger and present at a variable number of copies in 
comparison with a reference genome. The structural genomic variants are likely as 
important as SNPs, short tandem repeats (STRs), and other small changes in their 
contribution to genetic variation in humans. 
 
 
2 . 2 . 1 . 3  E p i g e n e t i c s  
 
Epigenetic modifications of the human genome are widely considered the important 
link between environment and the genome. The term 'epigenetics' accurately states 
'above the genetics'. Nowadays, it is generally used to refer to changes in gene 
expression without changing of the DNA sequence. The most intensely studied 
epigenetic changes are DNA methylation and histone modifications (78, 79). 
Epigenetic changes can be inherited mitotically in somatic cells, and thus 
environmental effects on the genome can have long-term effects on gene expression 
in different tissues. 
2.2.2 Linkage analysis 
 
The general paradigm for disease gene mapping, so called positional cloning, has 
emerged for as an efficient application for single gene disorders. It consists of 
identifying families, collecting DNA samples, genome-wide genotyping markers, 
linkage analysis, fine genetic and physical mapping, and mutation identification. 
The same strategy has been applied to complex disorders with very limited success. 
Only a handful of truly believable “gene identification” has been published. The 
main reasons for unsuccessful studies are a lack of statistical power, difficult 
phenotypes, and the fact that the underlying genetic variants generally only have a 
low risk ratio. 
Before starting genetic mapping, it should be evident that the disease has a genetic 
basis. It is not sufficient that the trait “runs in families”, rather there should also be 
data also from twin and adoption studies. 
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In this section I shortly review the linkage analysis, because it has been for years the 
main starting point for genetic studies of complex diseases. It should be mentioned 
that nowadays the genome-wide association studies are technically feasible, and 
even more cost-effective than linkage studies with multisatellite markers. 
Traditionally, the most common markers used for genome-wide studies are 
multisatellites (short tandem repeats, STR), which are di-, tri-, or tetranucleotide 
repeats (80, 81). Today, linkage studies, if performed, are usually done with SNPs. 
The advantage is that several highly automated high-throughput methods have been 
developed for SNP genotyping (82). 
Genetic linkage analysis refers to the ordering of genetic loci on a chromosome and 
then estimation of the genetic distances among them. The distances are determined 
on the basis of statistical findings. In linkage analysis one tests the hypothesis that a 
certain chromosomal region is transmitted to affected individuals in a non-random 
fashion. Linkage tests the recombination fraction () between two loci, usually a 
marker and a disease locus. It measures if there is statistically significant deviation 
from free recombination between the disease and the marker loci. The linkage 
analysis is performed in families having multiple affected individuals, and the 
statistical analyses are used to detect if a particular marker seem to segregate with 
the disease at a greater frequency than predicted by chance. The statistical 
significance is traditionally measured using a logarithm of odds (LOD) score (83). 
In practice, linkage is assumed, if the LOD score is equal to or greater than 3, which 
means that the likelihood of observing the result if the two loci are not linked is less 
than 1 in 1000). 
 
2.2.3 Association analysis 
 
The basic principle of association studies in genetics is simple: we merely need to 
identify alleles that systematically and repeatedly differ between affected and 
control individuals. Allelic association is a nonparametric approach to mapping 
disease genes. The power of association analyses in detectecting genetic 
contributions to complex diseases can be much greater than that of linkage studies 
(84). Allelic association of the variant can be explained by direct biological action of 
the polymorphisms (i.e. causative variant), or by linkage disequilibrium (LD) with 
the nearby susceptibility variant.  Linkage disequilibrium occurs when a particular 
marker allele lies so close to the disease susceptibility allele that these alleles will be 
inherited together over many generations. Therefore, the same allele will be detected 
in affected individuals in multiple apparently unrelated individuals or families. 
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2.2.3.1 Association analysis with dichotomised traits 
 
Association analysis can be conducted with the individual markers (usually with 
SNPs or multiallelic markers) or a combination of them, i.e. haplotypes. The 
simplest way to perform association analysis is to utilize case-control samples, but 
today it is also possible to perform analyses in family material. Association studies 
are generally considered more powerful than linkage studies when applied to 
complex traits having many susceptibility variants with low risk rations. Still, there 
are a number of potential pitfalls and limitations of association studies (85), many of 
which depend on the particular design, study aims and analytical framework used 
(86). Common errors in performing association studies include small sample size, 
subgroup analysis and multiple testing, random error, a poorly matched control 
group, overinterpretation of results, and positive publication bias. 
Two types of basic of settings for association analyses are case-control and family 
study. In basic case-control studies, a sample of affected individuals and a sample of 
well-matched unrelated controls are studied. The case-control study designs have 
been criticized for their potential spurious association owing to population 
stratification. Population stratification can occur when individuals are selected from 
two genetically different populations in different proportions in cases and controls, 
and thus the cases and controls are not matched for their genetic background (87). 
To avoid the problem of selecting controls, family-based association studies were 
developed. In the classical haplotype-relative risk (HRR) method, parental alleles 
are classified into those transmitted to affected children and those not transmitted. It 
compares allele frequency between the proband group and a control group, which is 
constructed from non-transmitted alleles (83, 88). The transmission disequilibrium 
test (TDT) also utilizes the same kind of control group, but by extracting data only 
from heterozygous parents (89, 90). A variety of extensions of TDT are currently 
available for overcoming the problems caused by missing or homozygous parental 
data, eliminating the effect of linkage when multiple siblings are present in a family 
(91-94). 
When testing for association, it is common to genotype multiple SNPs within the 
gene or gene regions. Testing each SNP separately leads to issues with multiple 
testing, and is not efficient when the SNPs are in high LD. One alternative is to use 
haplotypes rather than individual SNPs. Constructing haplotypes from individual 
SNPs can provide stronger evidence of a region being associated with the disease 
phenotype than can the use of individual markers. The Human Genome Project has 
produced an enormous amount of data on the haplotype structure of the human 
genome, which can now be utilized to better construct the haplotypes. 
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2.2.3.2 Association analysis with quantitative traits 
 
Both linkage and association analysis programs traditionally use dichotomized traits 
which classify individuals in the analysis as either affected or unaffected. Recently, 
it has been made possible to also analyze traits that are continuous by nature.  The 
quantitative trait locus (QTL) is any locus that contributes to a phenotype that is 
measured quantitatively. Currently, it is possible to perform linkage and association 
analyses with quantitative traits. It has been speculated that using quantitative traits 
would increase the power to detect linkage and association, because these traits may 
better capture the genetic nature of the examined trait. The classic example of such a 
trait is height. Variables can also be collected from tests of neurocognitive functions, 
which are deficient in individuals with schizophrenia and their relatives when 
compared to the general population (95). However, lessons from animal studies have 
shown that the number of loci, their relative effects, and how they interact with each 
other and the environment might vary considerably between phenotypes, indicating 
that some phenotypes might be better suited to QTL cloning than others (96). 
 
2.3 Genetics of schizophrenia 
2.3.1 Establishing the genetic component in schizophrenia 
 
Over many years a large body of data has been collected demonstrating that 
schizophrenia and the schizophrenia spectrum disorders have a major genetic 
component. It is also evident that the genetic basis of psychoses is not simple, i.e. there 
is no single gene causing schizophrenia, and that the genetic susceptibility to the 
disease is likely to involve several predisposing variants in the genome. 
Most studies of schizophrenia show that it runs in families. Twin studies of 
schizophrenia have shown consistently higher concordance in monozygotic (MZ, 
~46%) than dizygotic (DZ, ~9%) twins (10). Meta-analyses of twin studies have 
estimated the heritability of schizophrenia to be approximately 80% (97). In the 
adoption studies, an increased risk of schizophrenia was present in the biological 
relatives of individuals with schizophrenia (98). The lifetime morbidity risks (MR) 
for relatives of schizophrenic patients are shown in table 3.  Because twins also 
share prenatal and postnatal environments, the effect of genetics tends to be 
overestimated. However, across all adoption studies performed, increased risk of 
schizophrenia was present in the biological relatives of individuals with 
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schizophrenia (98). These findings indicate that schizophrenia have genetic basis, 
but it can not be explained by a single gene, rather of combination many risk genes. 
Schizophrenia is genetically mediated disease, but the contribution of the genetic 
component of it seems to be broader. In general, it seems that risk for all psychotic 
spectrum disorders (i.e. schizoaffective, schziophreniform, delusional, paranoid 
personality and schizotypal personality disorders) is increased in the relatives of 
schizophrenic individuals (99). Relatives of schizophrenic patients are probably not 
at increased risk for anxiety or alcohol and drug dependence disorders (100), but 
evidence concerning bipolar disorder is not totally clear: bipolar disorder and 
schizophrenia might have shared predisposing genetic factors (101). 
In conclusion, there is plenty of evidence that schizophrenia is at least genetically 
mediated although not necessarily genetically determined, making it reasonable to 
perform genetic studies on the disease. 
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Table 3. Morbid risk of schizophrenia for relatives of schizophrenic patients 
(adapted from Tsuang 2000 (10)) 
      
   
Relationship Shared genes (%) 
Risk 
(%) 
   
General population N.A. 1 
Spouses of patients N.A. 2 
Third-degree relatives  12.5  
     First cousins  2 
Second degree relatives 25  
     Uncles/aunts  2 
     Nieces/nephews  4 
     Grandchildren  5 
     Half-Siblings  6 
First-degree relatives 50  
     Parents  6 
     Siblings  9 
     Children  13 
     Siblings with 1 schizophrenic parent  17 
     Dizygotic twin  17 
Monozygotic twin 100 48 
Children with 2 schizophrenic parents 100 46 
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2.3.2 Previous genetic findings for schizophrenia 
 
2 . 3 . 2 . 1  C h r o m o s o m a l  a b n o r m a l i t i e s  
 
Individuals having Velo-cardia-facial syndrome (VCFS) carry a deletion in the 
chromosome 22q11 and have an increased risk for psychosis. Recent studies have 
suggested that about 25% of patients develop psychoses (102). Several studies have 
also demonstrated an increased prevalence of chromosome 22q11 deletions in 
people with schizophrenia (103-105). Pooled analyses from these studies suggested 
that 0.65% of people with schizophrenia had deletions at chromosome 22q11 (105). 
When samples were restricted to childhood-onset schizophrenia, 5.3% of patients 
carried the 22q11 deletion (106). The causative genes in this region remains 
unidentified, but three candidate genes are intensively studied: catechol-O-methyl 
transferase (COMT), proline dehydrogenase (PRODH2), and ZDHHC8. More 
discussion on this is found in the candidate genes section. 
A large multi-generational Scottish pedigree carries the chromosome 1 breakpoint of 
a balanced t(1;11) translocation that co-segregates with schizophrenia and related 
mood disorders (107, 108). The translocation disrupts three genes, the disrupted in 
schizophrenia 1 and 2 (DISC1, DISC2), as well as translin-associated factor X 
(TRAX). The DISC1 gene is the most intensely studied, and there is now growing 
evidence that this gene is involved in schizophrenia and other psychiatric diseases 
(108, 109). See the candidate genes section for more discussion. Furthermore, the 
gene encoding phosphodiesterase 4B (PDE4B) interacting with DISC1 was reported 
to be disrupted by a balanced translocation in a subject diagnosed with 
schizophrenia and a relative with chronic psychiatric illness (110).  
 
2 . 3 . 2 . 2  L i n k a g e  s t u d i e s  
 
Genetic linkage studies of schizophrenia have been carried out for more than two 
decades. The findings are inconsistent, and loci for predisposing genes for 
schizophrenia have been reported in almost all chromosomes (111).  I omit a more 
detailed review of the linkage studies in this thesis, because evidence from linkage 
studies has not been very fruitful. Some linkage studies are mentioned in the 
following section, if the proposed candidate genes are supposed to locate under 
previously identified linkage peaks. 
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2 . 3 . 2 . 3  C a n d i d a t e  g e n e s  
 
Schizophrenia—like most other complex traits in biomedicine—has been the subject 
of a number of genetic association studies (112, 113). A schizophrenia gene 
database (SchizophreniaGene) of the Schizophrenia Research Forum has already 
included more than 1,500 association studies which include almost 500 different 
genes (in April of year 2007). Hard evidence for any gene is still missing, but 
reports supporting the role of many proposed genes have appeared in respected 
journals known for rigorous peer review. Table 4 lists some promising candidate 
genes predisposing to schizophrenia. Below is a review of those candidate genes 
with most potential in playing a role in the molecular pathogenesis of schizophrenia. 
Studies of a Scottish pedigree with individuals with the balanced translocation 
between chromosomes 1 and 11 identified that the DISC1 and DISC2 genes are 
disrupted in chromosome 1 (114). There is as yet nothing more concrete to say about 
any possible impact of DISC2 on the psychiatric phenotype, but DISC1 is 
intensively studied. Several family studies, including two Finnish studies (115-120), 
have reported suggestive linkage between psychiatric illness and this 1q42 region 
using broad phenotype models. In our sample Hennah et al. reported association 
between haplotypes and schizophrenia in DISC1 (121). Several studies have also 
demonstrated association between DISC1 and schizophrenia, but inconsistency 
exists between markers, haplotypes, and the gene region (122-124). DISC1 is widely 
expressed, and seems to have a role in cytoskeletal regulation, and thus may affect 
neuronal migration, neurite outgrowth and intracellular transport (125, 126). A 
recent study demonstrated that mice with Disc1 missense mutations exhibited 
physiological, pharmacological, neuroanatomical, and behavioural features similar 
to schizophrenia phenotype. Futher these features could be reversed by antipsychotic 
treatment (127). 
The COMT gene works in the synthesis and degradation of catecholamines, and 
functional polymorphism (Val158Met) in the gene is under marked scrutiny for its 
role in schizophrenia. It is a functionally relevant candidate gene, and is located at 
the 22q11 deletion region of VCFS syndrome. Three meta-analyses of the 
association studies have been published with mixed results. Generally, the results 
have been negative (128, 129), but in one study COMT was associated with 
schizophrenia in European individuals (130). 
The deCODE Genetics group identified several risk haplotypes for schizophrenia 
around the neuregulin 1 (NRG1) gene on a linkage region they had identified on 8p 
(131) in Icelandic families. The findings have been replicated (132-137), although 
contradictory reports also exist (138-141), and there are inconsistencies concerning 
the associated markers, risk alleles, and haplotypes in both genes. The specific risk 
alleles and pathogenic mechanisms are unknown. NRG1 is expressed in synapses in 
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the brain and appears to be involved with expression and activation of 
neurotransmitter receptors (142). 
Several studies have found evidence for linkage of schizophrenia on 6p24-22 (143). 
Follow-up of the linkage peak in the Irish family set demonstrated a positive 
association in the dystrobrevin binding protein 1 or dysbindin (DTNBP1) gene 
(144). The association in this gene region has been replicated in several independent 
populations, but also? negative studies exist (145-150). The causative variant 
remains unidentified, and associated alleles and haplotypes have not always been 
macthing in all studies. The function of DTNBP1 in the brain is largely unknown. 
Expression of DTNBP1 is reduced in certain brain regions of schizophrenic patients 
at both RNA and protein levels (151, 152). Reduced protein expression is associated 
with additional changes consistent with a role in glutamatergic neurotransmission. 
The glutamatergic system is of great interest for schizophrenia liability. 
Overexpression of DTNBP1 is associated with increasedphosphorylation and 
activity of AKT1 in neuronal culture, suggesting that DTNBP1 also interacts with 
the AKT signaling pathway, which mediates cell survival (153). AKT1 is recently 
also associated with schizophrenia. 
The G-protein signaling 4 (RGS4) gene maps to the 1q21–q22 linkage region. 
Microarray studies of post-mortem brain samples of schizophrenic patients found 
altered expression of RGS4 in schizophrenia (154). A study of US and Indian 
pedigrees showed association with this gene (155). One replication study supported 
the RGS4 association with schizophrenia liability (156), whereas others have not 
(157, 158). 
Emamian and colleagues found evidence for the involvement of the AKT signaling 
pathway in the pathogenesis of schizophrenia (159). In addition to impairment of 
protein levels and phosphorylation patterns in the pathway, they detected association 
of v-akt murine thymoma viral oncogene homolog 1 (AKT1) SNPs and their 
corresponding haplotypes with the disease. Findings from this gene region have 
been replicated (160, 161), but a negative report also exists (162). 
The chromosome 13q14-32 linkage region harbors the D-amino acid oxidase 
activator (DAOA or G72) and G30 genes, which have been reported to be associated 
with schizophrenia (163). Evidence for epistasis was also observed for one pair of 
G30 and G72 genotypes, supporting a potential interaction between them in the risk 
for schizophrenia. There are now positive and negative reports on the role of these 
genes in schizophrenia (164-171). 
Several lines of evidence indicate that disturbances in -aminobutyric acid (GABA) 
neurotransmission may contribute to the development of psychiatric disorders, in 
particular schizophrenia (172-174). Among different receptor subunit combinations, 
the 1/2/2-containing heteropentamer is the most abundant GABA-A receptor 
subtype in mammalian brains (175), and the corresponding genes - the GABRA1, 
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GABRB2 and GABRG2 genes - are located in the chromosomal region 5q34. This 
region have been linked in several genome-wide scans to schizophrenia, including 
ours (176-182). The study conducted with Portuguese and German families reported 
association between markers of three cluster genes, GABRA1, GABRP, and 
GABRA6, and schizophrenia (183). The study with Han Chinese detected association 
between GABRB2 and schizophrenia (184), and the observation was replicated in a 
family-based study of Chinese origin (185), but at least one negative report also 
exists in a Japanese schizophrenia sample (186). 
In conclusion, none of the genes listed above is proven to be  
“the schizophrenia gene”. Nowadays, the DISC1, DTNBP1, NRG1 genes are the 
most promising, but further studies are needed. 
 
Table 4. Candidate 
susceptibility genes for 
schizophrenia.  
  
Gene Location 
  
5HT-2A receptor 13q14 
AKT1 14q32 
CHRNA7 15q13 
CLINT1 (Epsin4) 5q33 
COMT 22q11 
DAOA (G72) 13q33 
DISC1 1q42 
DTNBP1 6p22 
G30 13q33 
GABA-A receptors 5q34 
GRM3 7q21 
NDE1 16p13 
NRG1 8p12 
PPP2CC 8p21 
PRODH 22q11 
RELN 7q22 
RGS4 1q23 
TRAR4 6q23 
ZDHHC8 22q11 
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3 AIMS OF THE STUDY 
The aim of the present study was to investigate the genetic basis of schizophrenia 
and schizophrenia spectrum disorders in Finland by addressing the following 
specific aims: 
 
• To examine the role of the common variants in the three previously 
associated schizophrenia candidate genes, DTNBP1, NRG1, and AKT1 in 
the Finnish family sample (I) 
• To investigate the regional candidate genes on chromosome 5q31-34, 
previously linked to schizophrenia in the Finnish family sample. The 
analysed genes were five GABA-A receptor genes (GABRA1, GABRA6, 
GABRB2, GABRG2, and GABRP) and the Epsin 4 gene (ENTH) (II) 
• To explore the role of the maternal-fetal genotype incompatibility at the 
RhD locus in the susceptibilty of schizophrenia, and to develop statistical 
methods to enable these analyses (III, IV) 
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4 SUBJECTS AND METHODS 
4.1 Study subjects 
4.1.1 Schizophrenia family sample 
 
The Finnish schizophrenia study sample used here has been collected as part of a 
larger project that has been carried out in Finland from the beginning of the late 
1980s. Briefly, it includes individuals with schizophrenia born between 1940 and 
1976 who had a diagnosis of schizophrenia spectrum disorders at any time point 
between 1969 and 1991. Probands were contacted by their treating physician, with 
additional family members contacted only if the proband provided written informed 
consent. The research was approved by the Ministry of Social Affairs and Health 
(Finland) and the appropriate institutional review boards, and informed consent was 
obtained from the study subjects. Two psychiatrists or psychiatric residents made 
independent DSM-IV best-estimate lifetime diagnoses from all available inpatient 
and outpatient records for probands and their relatives. The schematic of the 
methods used for identifying probands is presented in figure 1. 
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Figure 1. Flow-chart describing the identification of subjects for the schizophrenia study 
from the registers. 
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4 . 1 . 1 . 1  S a m p l e  u s e d  i n  c a n d i d a t e  g e n e  s t u d i e s  ( I ,  I I )  
 
The complete study sample for the candidate gene analysis included 441 nuclear 
families consisting of 2,605 individuals, of which DNA was available for 1,864 
individuals. For analysis in this study we used only two of the liability classes, LC1, 
which represents core schizophrenia, and LC3, which is representative of the 
schizophrenia spectrum disorders, enlisted in 4.1.2. Of the 865 affected individuals, 
638 (74 %) and 865 (100 %) fulfilled the criteria for LC1 and LC3, respectively. 137 
out of the 441 nuclear families had one affected individual according to LC3, 214 
had two affected individuals, 67 had 3, 18 had 6, 4 had 5, and one family had seven, 
respectively. Of the affected individuals, 525 were males and 340 were females 
(LC3). There are slight differences in the numbers of the individuals in two papers 
(I, II) because of the difference in genotyping platforms used, but basically the 
sample is the same. 
In the first study (I), we divided the study sample into two geographical sub-
samples, one from a young internal isolate (IS) (181 families) and the other derived 
from the rest of Finland (AF) (268 families) (Figure 2). This division was based on 
the settlement history of Finland. The Finnish inhabitation of the internal isolate is 
well documented as beginning with the first immigrant in 1676, owing to legal 
records documenting inevitable conflicts with the native forager population, the 
Saami. About half of the immigrants of the region perished in the great famine of 
1695–1697, which also resulted in the gradual disappearance of the Saami people 
from the district. When the parish registers were established in 1718, the population 
in the 165 houses consisted of 615 individuals belonging to 39 families. During the 
subsequent century, when diseases repeatedly swept through more densely 
populated parts of Europe, population growth was rapid in rural parts of Finland; 
this expansion eventually made possible the growth of the internal isolate to its 
present population of over 18 000 (Figure 3). 
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Figure 2. The sample used in the studies (I, II). 
449 families
Isolate
181 families
All Finland
268 families
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Figure 3.  The settlement of the internal isolate utilized in the study. The 
inhabitation of the wilderness began in the 1500s in a small southeastern area of South Savo 
(shaded gray) to the central, western and finally northern parts of the country. Kuusamo was 
inhabited towards the end of this internal migration movement mainly by families from 
Ostrobothnia and from South Kainuu; both groups have their ancestral roots in South Savo. 
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4 . 1 . 1 . 2  S a m p l e  u s e d  i n  m a t e r n a l - f e t a l  
i n c o m p a t i b i l i t y  i n  t h e  R h D  l o c u s  s t u d i e s  ( I I I ,  I V )  
  
The study sample consists of the sub-sample of the previously described sample. 
The sample includes 181 trios with 450 individuals, and was composed of 88 
patient-parent trios, 72 patient-mother pairs, and 21 patient-father pairs. Of the 181 
patients, 112 were male (62%), 147 were second- or subsequently-born (81%), 145 
had received a diagnosis of schizophrenia (80%), 25 had received a diagnosis of 
schizoaffective psychosis disorder (14%), and 11 had received a schizophrenia 
spectrum diagnosis (6%). Approximately 12% of mothers and 6% of fathers fell into 
one of those three diagnostic categories. Patients were born during the period 1937–
1973, with a median birth year of 1957. Prophylaxis against maternal 
isoimmunization was started after 1969, and thus was not available for the vast 
majority of the patients in the study since only three patients were born after it (187). 
 
4.1.2 Clinical diagnosis 
 
All available inpatient and outpatient records were collected for probands and 
relatives with any psychiatric diagnosis in any of the three registers. Two 
independent psychiatrists made Diagnostic and Statistical Manual of Mental 
Disorder, Fourth Edition (DSM-IV), (American Psychiatric Association 1994) best-
estimate lifetime diagnoses. If these two psychiatrists provided conflicting 
diagnoses, a consensus was obtained using a third reviewer. Owing to the difficulty 
in determining whether an individual is truly unaffected, all unaffecteds were given 
a disease status of unknown. The register diagnosis of schizophrenia has been 
shown, in several studies, to have a high reliability. Agreement between different 
psychiatrists on lifetime diagnosis has been shown to be good using the method 
described above (5, 188-190). 
Affected individuals were divided into three increasingly inclusive liability classes 
(LC) according to the consensus diagnoses. The narrowest class was LC1, consisting 
only of individuals with core schizophrenia. LC2 added individuals with 
schizoaffective disorder, and LC3 added those with schizophrenia spectrum 
conditions (schizoid, schizotypal and paranoid personality disorders, 
schizophreniform, delusional and brief psychotic disorders, and psychotic disorder 
not otherwise specified). The complete study sample included 441 nuclear families 
consisting of 2,605 individuals, of which DNA was available for 1,864 individuals. 
For analysis we used only two of the liability classes, LC1 which represents core 
schizophrenia and LC3 which is representative of the schizophrenia spectrum that 
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are most likely to have similar underlying genetic variants (191). Of the 865 affected 
individuals, 638 (74 %) and 865 (100 %) fulfilled the criteria for LC1 and LC3, 
respectively. 137 out of the 441 nuclear families had one affected individual 
according to LC3, 214 had two affected individuals, 67 had 3, 18 had 6, 4 had 5, and 
one family had seven, respectively. Of the affected individuals, 525 were males and 
340 were females (LC3). 
4.1.3 Neurocognitive variables 
 
A neuropsychological test battery was administered to 746 subjects in a fixed order. 
The test battery is a series of tests that uses well validated, internationally used 
neuropsychological instruments to evaluate an individual’s cognitive ability.  These 
tests have been shown to fullfil most of the criteria of endophenotypes for 
schizophrenia (192-194). Shortly, following criteria are proposed for 
endophenotypes: 1) the endophenotype is associated with illness in the population, 
2) the endophenotype is significantly heritable, 3) the endophenotype is present in 
individuals with and without an active phase of the illness, 4) in families with the 
illness, also the unaffected relatives have the same endophenotypic trait, and 5) the 
endophenotype that is present in the affecteds, is more prevalent in the unaffecteds 
in the family than in general population (195). Test includes auditory verbal 
attention and verbal working memory which measured with the Digit Span forward 
and backward tests from the Wechsler Memory Scale – Revised (WMS-R), 
respectively (196). Visual attention and working memory were measured with the 
Visual Span forward and backward tests, respectively, from the WMS-R. The 
California Verbal Learning Test (CVLT) (197) was used as a test for verbal learning 
and memory. From the CVLT, we included the following variables: total recall from 
trials 1-5 (learning), semantic clustering as a learning strategy, perseverative and 
intrusive recall errors, and recognition memory. In addition, the interference score of 
the Stroop Task (197) was used as a measure of executive functioning. Basic 
cognitive ability was examined with the Vocabulary subtest from the Wechsler 
Adult Intelligence Scale-Revised (WAIS-R) (196). 
4.2 Laboratory methods and statistical analysis 
 
Methods used in this study have been described in detail in the original articles (I-
IV) and are listed table 5. The methods used were generally common in the field of 
the human genetics. The maternal-fetal-genotype test was developed for this study.  
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Table 5. Methods used in the present study  
    
  
Method Original publication 
    
  
Laboratory procedures  
  DNA extraction I, II, III, IV 
  Polymerase Chain Reaction (PCR) I, II, III, IV 
  Agarose gel electrophoresis I, II, III, IV 
  Restriction enzymes III, IV 
  Sequenom MALDI-TOF mass spectrometry I, II 
  TaqMan with an ABI Prism 7900 II 
  
Statistical methods  
  Pedcheck 1.1 I, II, III, IV 
  Downfreq 2.1 I, II 
  MLINK/LINKAGE I, II 
  Homog 3.35 I, II 
  Analyze I, II 
  FBAT I, II 
  Haploview I, II 
  QTDT II 
  Simwalk 2.81 II 
  TDT III, IV 
  Mendel 4.0 III, IV 
  MFG test III, IV 
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5 RESULTS AND DISCUSSION 
5.1 Association analysis of three candidate genes (I) 
 
After years of candidate gene studies with inadequate sample sizes, and without 
consistent replications, two genes were reported to associate with schizophrenia with 
rather convincing data in the year 2002. The dystrobrevin binding protein 1 or 
dysbindin (DTNBP1) gene was located under the linkage peak on chromosome 6p24-
22 (198). The deCODE Genetics group form Iceland found association to neuregulin 1 
(NRG1) gene on a linkage region on 8p (131). After initial studies several replication 
attempts have been carried out with somewhat contradictory results. 
The majority of the studies for both genes have found evidence of association with 
at least a couple of markers in the same gene regions, but no single high-risk 
haplotype is associated across all samples. The general rules for replications studies 
are still unspecified by the scientific community, and it is unclear whether we should 
expect to observe association with the same specific haplotype, or only with the 
gene, across samples. For common disorders such as schizophrenia, it is crucial to 
try to replicate the findings of others so that we can evaluate the validity of the 
proposed susceptibility genes. Further, the genetic studies are not sufficient, and also 
functional evidence is needed to support the role of certain variants in the gene.   
We wanted to study the role of these two genes in the background of schizophrenia 
in Finland in our relatively large family material and possibly find support that 
NRG1 and DTNBP1 could be genetic risk factors in our population. Later in 2004 
Emamian and colleagues reported in Nature Genetics that the AKT signaling 
pathway is possibly involved in the pathogenesis of the disease (159). The variants 
in the v-akt murine thymoma viral oncogene homolog 1 (AKT1) were associated 
with schizophrenia. Because our assay design was at a stage where new SNPs could 
still be added, we also included the SNPs from the AKT1 gene. 
We studied 15 SNPs from DTNBP1, 10 form NRG1, and 3 from AKT1. The 
coverage of the most common haplotypes with these SNPs in DTNBP1 was 
relatively good, and in addition, eight SNPs of our study were also included in the 
original article published by Straub and colleagues (144). We ended up with only 10 
SNPs in NRG1, most likely not capturing all of the common allelic diversity. NRG1 
is a very large gene spanning approximately 1.4 Mb, and it has more than 20 exons 
giving rise to at least 15 isoforms. Nevertheless, we had two of the SNPs from the 
originally associated Icelandic haplotypes (131), and quite a few from the previously 
associated 3´end of the gene region (133, 136, 199, 200). AKT1 is a very small gene, 
and with 3 SNPs we acquired enough information to cover common haplotypes from 
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the gene region. The LD diagrams and the location of studied SNPs in relation of 
previous findings are presented in the first article. 
We did not detect any association with DTNBP1 or with AKT1 to DSM-IV-based 
diagnosis of schizophrenia or schizophrenia spectrum disorder. We found suggestive 
evidence of association in the 3´end of NRG1, but these results are not significant 
after correction for multiple testing. Haplotype analyses yielded no further evidence 
for association. The modest association seems to come from the All Finland sub-
sample, since no association was detected in the Isolate sub-sample. The exact p-
values are presented in the table 6, which is also published in the article. It is 
noteworthy, that there is a suggestive evidence of association between the core 
schizophrenia and DTNBP1 when performing mixture model clustering of extensive 
clinical and neurobehavioural data collected from schizophrenia families to produce 
novel subclasses in a non-supervised manner (unpublished data). 
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Table 6. Association results of DTNBP1 , AKT1, and NRG1 for the whole study sample and
the two sub-samples: isolate (IS) and the rest of Finland (AF). (Original publication I).
  
Gene Marker LC1 LC3 LC1 LC3 LC1 LC3
DTNBP1 D6S1721 0.363 0.637 0.129 0.526 0.872 0.908
rs1047631 0.853 0.487 0.558 0.434 0.483 0.935
rs742106 0.19 0.306 0.263 0.386 0.62 0.647
rs875462 0.374 0.37 0.353 0.289 0.815 0.972
rs1040410 0.417 0.269 0.91 0.838 0.109 0.08
rs742105 0.726 0.575 0.562 0.323 0.659 0.505
rs760666 0.852 0.632 0.936 0.727 0.832 0.733
rs2619539 0.833 0.429 0.668 0.378 0.851 0.975
rs2743867 0.541 0.896 0.188 0.255 0.355 0.12
rs1011313 0.436 0.546 0.076 0.053 0.295 0.092
rs2619528 0.473 0.347 0.872 0.896 0.189 0.047
rs2619522 0.22 0.086 0.558 0.419 0.135 0.024
rs2743854 0.435 0.238 0.912 0.751 0.219 0.085
rs1997679 0.647 0.678 0.332 0.282 0.531 0.395
rs909706 0.67 0.573 0.546 0.208 0.698 0.258
rs2769561 0.219 0.204 0.636 0.632 0.115 0.078
D6S285 0.052 0.01 0.047 0.016 0.553 0.652
NRG1 D8S1820 0.398 0.4 0.358 0.469 0.895 0.832
SNP8NRG221132 0.414 0.698 0.315 0.241 0.918 0.224
rs6994992 0.268 0.165 0.323 0.141 0.684 0.776
rs1503487 0.046 0.331 0.045 0.246 0.763 0.929
rs1023911 0.16 0.187 0.027 0.05 0.354 0.502
rs1481747 0.481 0.788 0.892 0.665 0.317 0.754
D8S1477 0.065 0.216 0.403 0.613 0.209 0.431
rs3924999 0.026 0.048 0.035 0.04 0.359 0.497
rs3808368 0.838 0.979 0.995 0.581 1 0.448
rs764059 0.019 0.012 0.03 0.012 0.36 0.485
rs2919378 0.093 0.029 0.239 0.019 0.212 0.588
rs3735782 0.021 0.093 0.101 0.138 0.101 0.42
D8S1110 0.309 0.191 0.42 0.28 0.865 0.808
AKT1 D14S260 0.582 0.769 0.611 0.549 0.731 0.564
rs2494732 0.612 0.293 0.615 0.389 0.879 0.547
rs2498799 0.462 0.699 0.118 0.172 0.296 0.264
 rs1130214 0.52 0.414 0.258 0.106 0.44 0.178
Combined AF IS
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In conclusion, it seems that DTNBP1, AKT1, and NRG1 do not play major roles in 
the pathogenesis of schizophrenia in Finland, at least in our family material. The 
allelic variants in NRG1 should be studied in more detail to better address the 
potential role of these variants. Even though our sample size is fairly large, it is still 
possible that these three genes are susceptibility genes for psychosis in Finland and 
that our study merely lacked the detection power to show this. Regardless, our study 
is for now ‘a case against’ that these genes are predisposing for schizophrenia. 
Generally speaking, there is no solid agreement in psychiatric genetics on what 
constitutes a true replication. There are several possible definitions: 1) same gene 
region, 2) same haplotypes, 3) same variants, and 4) same alleles. Strictly speaking, 
a true replication should consist of the same alleles of the same marker being 
associated with the phenotype, as observed in the original report. In figure 3 is a 
summary of published positive findings for DTNBP1. Even if positive findings 
outnumber the negative ones, there is no single marker that has been consistently 
associated with the disease. It can be argued, that because we do not have the 
‘causative’ variant, it could be that the haplotype structure of the gene region is 
different in every populations, and thus resulting inconsistent alleles or haplotypes. 
Mutsuddi and colleagues showed that this is not the case with DTNBP1 (201). They 
demonstrated that the studied European-derived populations have haplotype patterns 
and frequencies that are consistent with HapMap CEU samples (and each other). 
Thus, it is unlikely that population differences are creating the inconsistency of the 
association studies.  
It should be noted that even if the register diagnosis of schizophrenia has been 
shown to have a high reliability, there has been studies that question this method.  
The Finnish studies showed clinicians do not make the diagnosis of schizophrenia as 
often as the application of operational criteria would suggest they should (202, 203). 
The discordance between clinical diagnosis and the research, operational diagnosis 
was in particular likely in patients having late onset and few contacts to psychiatric 
hospital. However, this should not bias our results extensively, because we usually 
only use affected individuals in our analysis and treat others as unknown of their 
status of disease. 
Based on these pieces of evidence, it appears that the evidence of association 
between DTNBP1, AKT1, and NRG1 with schizophrenia is at present, equivocal and 
unsatisfactory and that further studies are needed. Ideally, all the samples should be 
genotyped in the same place and the analyses carried out on the combined material.  
Only then can we truly evaluate the role of these genes. 
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Figure 4.  Specific DTNBP1 alleles and haplotypes associated with schizophrenia 
across studies. DNTBP1 markers tested for association with schizophrenia in previous reports 
(p<0.05) and in the current study (original publication I). 
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5.2 Association analysis of the linkage region on chromosome 
5q31-34 (II) 
 
We have conducted a genome-wide scan in a study sample of 238 pedigrees 
collected nationwide in Finland and identified linkage to loci on 1q42, 2q37 and 
5q21-33 (176, 204). Encouragingly, the chromosome 5q linkage finding is replicated 
in several studies and multiple independent populations (205), and was among one 
of the regions likely to contain loci that increase susceptibility to schizophrenia in a 
recent meta-analysis of 20 schizophrenia genome scans from diverse populations 
(206). Our original aim was to identify allelic variants of genes on 5q31-34 that 
associated with schizophrenia, as suggested by the previous linkage finding in 238 
Finnish schizophrenia families. In the figure 4, linkage results from chromosome 5 
from the late settlement region of the Finland are presented. 
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Figure 5.  Profile for the multipoint non-parametric linkage (NPL) scores at 5q31-
34 calculated using Simwalk2 software. Only one statistic (STAT A) is presented. The x-axis 
presents location on the chromosome in Mb. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Genomic structure of the chromosome 5q GABAA receptor subunit 
genes and the CLINT1 gene. Gene Orientation is indicated by the direction of the arrows. 
Physical distances between genes are shown (Mb). 
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The GABA signalling system has been widely proposed to be involved with 
schizophrenia pathogenesis (for a detailed review see (207)). Although, we lack 
definitive evidence for involvement of the GABA signalling pathway, multiple line 
of evidence are building up. Postmortem schizophrenic brain samples exhibit a 
spectrum of alterations with respect to GABAA receptor binding  (172), GABAA 
subunit mRNA levels (183, 208-211), and also some subunit protein expression 
(212, 213). Recently, suggestive genetic evidence for involvement of chromosome 5 
GABAA-receptor subunits has been published. Petryshen and colleagues reported 
association between schizophrenia and SNPs of the chromosome 5 GABAA cluster 
genes, GABRA1, GABRP, and GABRA6 (183). Subsequently, Lo and colleagues 
detected an association between GABRB2 and schizophrenia among Han Chinese 
(184), and the finding was confirmed in Chinese schizophrenic patients (185). After 
these findings were published we focused our attention on these functionally and 
genetically promising genes. Later, Pimm and colleagues reported association to 
Epsin 4 (CLINT1) in the same region, and we decided to add this gene to our study. 
GABA is the major inhibitory neurotransmitter found in the brain. GABA is 
synthesized from its precursor, L-glutamate, by the enzyme glutamate decarboxylase 
(GAD). Three GABA receptors types have been identified. GABAA and GABAC 
receptors are ionotropic (i.e. composed of subunits which cluster together to form an 
ion channel), but the GABAB receptor is metabotropic and linked via a G-protein to a 
signalling pathway. GABAA is a heteropentameric receptor composed of five subunits: 
two copies of  and  each and one copy of either , , or  subunits. The most 
common receptor configuration of the total GABAA receptor subtypes is 122. It is 
widespread throughout the brain compared with other configurations located in more 
selective regions (214). It is noteworthy that genes encoding these three subunits are 
all located in the chromosome 5 GABAA-receptor cluster (figure 5).  
Epsin 4 encodes a protein known as Enthoprotin, which links clathrin coated 
neurotransmitter vesicles to the neuronal membrane. It has a function in regulating 
the reuptake and storage of neurotransmitters in the brain. 
We found association between individuals SNPs and haplotypes in the GABRG2 
gene (p = 0.002 for LC1 and p = 0.005 for LC3). Results are presented in the table 7, 
which is also published in the article 2. Locations of the SNPs in GABRG2 are 
presented in figure 6. We also found evidence for association in GABRB2 with 
single SNPs, but the haplotype analysis did not support these findings. We found 
that the most common haplotype, having a frequency of 0.65 was most significantly 
associated with the disease, both for schizophrenia (p=0.00014 for LC1) and for 
schizophrenia spectrum disorders (p = 0.00062 for LC3), and the haplotype was 
overtransmitted to affected individuals. We have data of neuropsychological tests 
from 664 individuals, and used them as quantitative variables. We found suggestive 
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evidence that the same variants are associated with working memory (Table 3 in II). 
No association was observed with CLINT1. 
In recent studies concerning the chromosome 5 GABA receptor subunits, different 
subunits were found to be associated with schizophrenia. This can be due to these 
being false positive findings, or may represent the complex genetic background of 
this region in relation to susceptibility to schizophrenia. It should be noted that 
causative variants remain to be identified, and furthermore, there is no solid proof 
that the found association has anything to do with GABA-receptors. They can 
merely be associated with this genomic region, or it can harbour a regulatory region 
which controls genes in other locations. If these associations truly point to a gene in 
this region, the GABAA-receptor is as of now the most likely candidate. 
Deficits in working memory are among the cognitive disturbances reported in 
schizophrenia (192, 194, 215-217). Working memory has been linked to dorsolateral 
prefrontal cortex activity (218, 219) as well as to the temporal cortex and a variety 
of subcortical structures. The dorsolateral prefrontal cortex has been shown to be 
damaged in schizophrenic patients (220), and imaging studies have linked prefrontal 
disturbances to working memory deficits in the individuals with schizophrenia  (216, 
217, 221). The GABA signaling pathway has been associated with working memory 
processes in the prefrontal cortex in monkeys (222, 223), and GABA has also been 
implicated in the temporal cortex and subcortical brain areas involved in working 
memory (224, 225). Our suggestive association between working memory and 
GABRG2 is in line with earlier functional studies. 
In conclusion, this study provides evidence of involvement of the GABAA receptor 
genes, particularly GABRG2, in pathogeneisis of schizophrenia in Finland. 
Furthermore, GABRG2 seems to affect working memory functions of the brain. The 
evidence for the involvement of chromosome 5 GABAA-receptor genes in the 
pathogenesis for schizophrenia is suggestive, and further studies are needed. All 
common variants should be identified and the genomic structure of the region 
clarified. After this, extensive collaborative studies should be carried out to address 
the role of this region and these genes in the etiopathogenesis of psychosis.    
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Table 7. Association results of the CLINT1 and GABA-A receptor genes. Black
and grey bars indicate haplotype blocks. For each haplotype, global haplotype 
association result is presented, and if it is significant (p<0.05) the best individual  
haplotype association result is also given. P-values below 0.05are indicated in bold.
Gene rs# LC1 LC3 LC1 LC3
Global Individual Global Individual
CLINT1 rs2270811 0.589 0.987
rs406150 0.864 0.566 0.34 0.247
rs10515754 0.13 0.402
rs10515753 0.906 0.351
rs1186930 0.695 0.556
rs10046055 0.9 0.813
GABRB2 rs168697 0.883 0.407
rs252965 0.242 0.368
rs252980 0.073 0.149 0.11 0.066
rs153296 0.064 0.009
rs173766 0.004 0.002 0.15 0.197
rs187269 0.072 0.092
rs194072 0.508 0.865
rs1816071 0.078 0.056
rs2617504 0.123 0.208
rs2910305 0.499 0.823 0.79 0.364
rs7714930 0.065 0.038
rs7724146 0.504 0.123
rs2964775 0.223 0.29
rs2962406 0.312 0.523
rs11748071 0.432 0.848 0.36 0.502
rs4426954 0.617 0.846
GABRA6 rs2197414 0.957 0.795 0.83 0.769
rs3811992 0.984 0.906
rs3811991 0.721 0.521
Single SNP Haplotype
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Table 7. Continues.
Gene rs# LC1 LC3 LC1 LC3
Global Individual Global Individual
GABRA1 rs4340950 0.828 0.77 0.94 0.972
rs4263535 0.748 0.9
rs7734447 0.194 0.368 0.3 0.013 0.01178
rs4260711 0.36 0.545
rs6878494 0.473 0.943
rs1350376 0.254 0.252
rs998754 0.136 0.132
GABRG2 rs209332 0.454 0.95
rs209336 0.594 0.991
rs209354 0.659 0.282 0.18 0.101
rs209357 0.143 0.035
rs211017 0.583 0.888
rs211029 0.191 0.087 0.34 0.191
rs210985 0.472 0.886
rs169792 0.027 0.028
rs211015 0.114 0.113 0.0022 0.00014 0.005 0.00062
rs211014 0.114 0.386
rs418210 0.093 0.083
rs424740 0.228 0.34
rs401750 0.011 0.018
rs647625 0.338 0.791
rs1422829 0.494 0.058
GABRP rs732157 0.664 0.898 0.98 0.76
rs1158443 0.807 0.739
rs9313525 0.377 0.613
rs1063310 0.475 0.681
Single SNP Haplotype
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Figure 7. Genomic structure of the GABRG2 gene and the locations of SNPs. 
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5.3 Maternal-fetal genotype incompatibility at the RhD locus (III, IV) 
 
Epidemiological studies have demonstrated that problems in the environment of the 
developing fetus during pregnancy can increase the risk for schizophrenia (11) with 
a general estimate for risk ratio of about 2.0. Genes can be associated with disease 
through an individual's inherited genotype, the maternal genotype or via an 
interaction between these two. Rh (Rhesus) incompatibility has been implicated as a 
risk factor among obstetric complications for schizophrenia (11, 29). In a meta-
analysis including three studies the overall odds ratio was estimated to be 2.0 (11). 
When these kinds of study designs are used, it is impossible to evaluate whether the 
effect of the RhD locus results from a maternal-fetal genotype incompatibility, or 
from linkage and association with a susceptibility allele at or near the RhD locus. 
Because existing statistical models and tests for gene detection are not optimal or 
even appropriate for identifying maternal-fetal incompatibility  loci, a maternal-fetal 
genotype incompatibility test (MFG) was developed (226), and method applied to 
genotype data from our schizophrenia family material. We genotyped the RhD locus 
in our family sample including 181 trios with 450 individuals. The MFG model is a 
modification of the case-parent-trio log-linear modelling approach (227, 228), and is 
sensitive to the effects of RhD maternal-fetal genotype incompatibility. It is able to 
identify the effects of the risk allele located at or near the RhD locus. 
We tested the hypothesis of an RhD maternal-fetal genotype incompatibility effect 
in the possible presence of LD. We observed significant evidence for an RhD 
maternal-fetal genotype incompatibility (p = .027). A one-sided test was used in the 
analysis, because we were replicating previous findings, and our hypothesis was that 
an RhD maternal-fetal genotype incompatibility increases risk to the developing 
fetus for later schizophrenia. We also ruled out the possibility that the finding is due 
to linkage or association. There was no evidence of linkage/association with 
schizophrenia at or near the RhD locus using a modification of the MFG test. 
Furthermore, we tested for linkage or association between schizophrenia and the 
RhD locus and nearby microsatellite markers nearby (D1S368, D1S552, RHD, 
D1S1622, and D1S513). We detected no evidence for linkage or association with 
schizophrenia at any of these loci. These results demonstrated that observed 
association is due to maternal-fetal genotype incompatibility. 
Our finding replicates earlier epidemiological findings, and demonstrates that the 
effect comes from to maternal-fetal genotype incompatibility rather than from an 
association with nearby markers. Furthermore, our estimate of the incompatibility 
parameter, in other words the modelling risk ratio, was 2.6. Cannon and colleagues 
estimated in the meta-analysis that the risk ratio is 2.0 (11), and Hollister and 
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colleagues found it to be 1.8 in their study (29). These findings are fairly similar, 
suggesting that the overall risk ratio of Rh incompatibility leads to a two-fold 
increased in the risk for schizophrenia. 
This finding has encouraged us also to investigate other blood groups that can lead 
to maternal-fetal genotype imcompatibilities. Schizophrenia and human leukocyte 
antigen (HLA) matching between couples or between mothers and offspring have 
independently been associated with prenatal/obstetric complications. We analysed 
HLA-A, -B, and -DRB1 as risk factors for schizophrenia. We detected significant 
HLA-B maternal-fetal genotype-matching effects on schizophrenia in female 
offspring (229). Furhermore, we are currently analysing the ABO blood group. 
Our study was conducted with individuals born before RhD prophylaxis in Finland 
and thus it is not possible to evaluate the role of prophylaxis in decreasing the 
relative risk for schizophrenia. These kinds of studies should be conducted to better 
understand the relation of RhD maternal-fetal genotype incompatibilities to 
schizophrenia risk. 
Sometimes DNA from the all family members is not available, but serotypes of 
individuals are. Adding these serotypes to the analysis could increase the power to 
detect maternal-fetal genotype incompatibilities. Consideration of incomplete data 
resulting from using non-codominant data requires substantial modification to the 
MFG statistical model so that serotypes can be used in the analyses. In the fourth 
article, we have made extensions to the MFG model in order to analyze serotypes 
along with genotypes. We demonstrated the usefulness of this model with our data 
from Finnish schizophrenia families. In addition, simulations show that the power to 
detect the MFG incompatibility effect is similar for trio samples comprised of 
genotypes alone and for trio samples comprised of a combination of genotypes and 
serotypes. 
In conclusion, the need to better elucidate the genetic basis of complex traits led us 
to develop a new statistical method, the MFG test, in order to test more realistic 
hypotheses regarding genetic effects. Because large samples are typically needed, 
the optimal use of different kinds of incomplete data is important. We have shown 
that the MFG method can be used to detect maternal-fetal genotype 
incompatibilities, and further that the statistical power can be increased by also 
including incomplete data such as serotypes. 
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6 CONCLUDING REMARKS AND FUTURE 
PROSPECTS 
The basis of this study has been the collaboration of many experts from several 
fields to collect a schizophrenia family sample from Finland. Without the extensive 
work of many people these kinds of studies could not be conducted. 
In recent years association studies have been leading the way toward 
characterization of the genetic background of schizophrenia. Unfortunately, lack of 
consistent replication for the same markers and haplotypes across studies has 
complicated the field of neuropsychiatric genetics. The collaboration of groups 
studying psychiatric illnesses throughout the world should be encouraged, and 
replication attempts should always preferably be conducted with the same markers 
as in the original studies. In this work, we have tried to replicate findings implicating 
some proposed schizophrenia candidate genes (DTNBP1, NRG1, and AKT1), but we 
conclude that these genes are not major risk factors for DSMIV-based diagnosis of 
schizophrenia or spectrum disorder in Finland. In the previously linked region on 
chromosome 5q, we studied the GABAA receptor cluster genes and CLINT1, and 
found evidence of association between GABRG2 and schizophrenia. Further studies 
in different populations are warranted to evaluate the significance of this finding, 
and eventually meta-analysis should be conducted. 
There is growing evidence that obstetric complications increase a child’s risk for 
developing schizophrenia in later life. In the search for predisposing genes to 
complex diseases, we have to develop better analysis methods to capture the 
underlying genetic mechanism. In this work, we developed the maternal-fetal 
incompatibility (MFG) method in order to analyze genotype mismatch effects 
between mother and fetus. We demonstrate that incompatibility at the RhD locus 
increases the fetus’ risk for schizophrenia two-fold. 
In general, association studies of some complex human genetic diseases have 
produced unambiguous, consistent, and clear-cut replication. These diseases include 
type 1 and type 2 diabetes as well as other autoimmune diseases, inflammatory 
bowel diseases, and age-related macular degeneration. The schizophrenia literature 
supports the connection between genetic variations at least in the NRG1, DNTBP1, 
and DISC1 genes and schizophrenia, but lacks impressive consistency in the precise 
genetic regions and alleles implicated. In the future, the study of the genetics of 
complex diseases will undoubtedly shed light on the pathogenesis of many ailments. 
However, whether these approaches will work for all diseases, especially in the case 
of psychiatric disorders, remains unknown. 
There is growing appreciation that the human genome contains significant numbers 
of structural rearrangements, such as insertions, deletions, inversions, and large 
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tandem repeats. Recent studies have found that approximately 5% of the human 
genome is structurally variable in the normal population, involving more than 800 
independent genes. As schizophrenia seems to be at least partly a 
neurodevelopmental disorder and some individuals with schizophrenia show 
cognitive decline, it could be that part of the disease is explained by rare structural 
rearrangements disturbing important genes for brain development. 
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